A randomized trial comparing cisplatin plus 5-fluorouracil with or without levamisole in operable gastric cancer.
- Author:
Jong Soo CHOI
1
;
Kyoo Hyung LEE
;
Myung Ju AHN
;
Jung Shin LEE
;
Je Han LEE
;
Dae Young ZANG
;
Chel Won SUH
;
Sang We KIM
;
Woo Gun KIM
;
Jin Cheon KIM
;
SukKoo KIM
;
Kun Choon PARK
;
Moo Song LEE
;
Sang Hee KIM
Author Information
1. Section of Hematology-Oncology, College of Medicine, University of Ulsan, Seoul, Korea.
- Publication Type:Original Article ; Clinical Trial ; Comparative Study ; Randomized Controlled Trial
- MeSH:
Adjuvants, Immunologic/administration & dosage*;
Adult;
Aged;
Antineoplastic Agents, Combined/therapeutic use*;
Antineoplastic Agents, Combined/adverse effects;
Cisplatin/administration & dosage;
Comparative Study;
Female;
Fluorouracil/administration & dosage;
Human;
Levamisole/administration & dosage*;
Male;
Middle Age;
Stomach Neoplasms/mortality;
Stomach Neoplasms/drug therapy*
- From:The Korean Journal of Internal Medicine
1997;12(2):155-162
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: To determine the effectiveness and toxicity when levamisole was added to the adjuvant combination chemotherapy in patients with operable gastric cancer. METHODS: After en bloc resection of gastric cancer without gross or microscopic evidence of residual disease from April 1991 to December 1992, 100 patients were randomized to 6 months of 5-fluorouracil 1,000 mg/m2/day administered as continuous infusion for 5 days, cisplatin 60 mg/m2/day as intravenous infusion for 1 day with or without levamisole (50 mg every eight hours P.O for a period of three days every 2 weeks for 6 months). This chemotherapy treatment was begun within 2 to 4 weeks after the surgery. The chemotherapy consisted of discrete 5-day courses administered at 4-weeks intervals. All 100 patients are assessable. RESULTS: The fifty patients were assigned to each treatment group. There was no statistical difference and no bias in the distribution of characteristics of the 100 evaluable patients between the two groups. A total of 274 courses of treatment were given in the levamisole group and 260 courses of treatment in non-levamisole group. Eleven patients in each group did not finish planned 6 courses of treatment mainly due to non-compliance. At median follow up of 39 months, 32 patients relapsed 19 in the levamisole group and 13 in the non-levamisole group (p = 0.284). Twenty five patients died of relapsed diseases, 15 in the levamisole group and 10 in the non-levamisole group. The levamisole group tended to show more risk of overall death rate and recurrence than the non-levamisole group. However, this result was not statistically significant at 3 years. The treatment was well tolerated in both treatment groups. The grade 2-3 toxicities were nausea/ vomiting (levamisole, non-levamisole group; 31.7%, 29.3% of treatment courses respectively), diarrhea (7.6%, 8.4%), mucositis (11.6%, 12.3%), and leukopenia (9.8%, 9.6%). CONCLUSION: Levamisole had negative effects on disease-free survival and overall survival when added to adjuvant combination chemotherapy of cisplatin and 5-fluorouracil in patients with operable gastric cancer. Both treatment arms were generally well tolerated and the toxicity profile was similar with or without levamisole.
